Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3

SIMPLE SUMMARY: The enzyme aldo-keto reductase 1C3 (AKR1C3) is present in several cancers, in which it is capable of actively metabolising different chemotherapy drugs and decreasing their cytotoxic effects. Therefore, the combination with specific inhibitors of AKR1C3 might prevent drug metabolism...

Descripción completa

Detalles Bibliográficos
Autores principales: Morell, Anselm, Čermáková, Lucie, Novotná, Eva, Laštovičková, Lenka, Haddad, Melodie, Haddad, Andrew, Portillo, Ramon, Wsól, Vladimír
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764606/
https://www.ncbi.nlm.nih.gov/pubmed/33322571
http://dx.doi.org/10.3390/cancers12123731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764606/
https://www.ncbi.nlm.nih.gov/pubmed/33322571
http://dx.doi.org/10.3390/cancers12123731

Ejemplares similares